1. From the editors

   • Greg L. Plosker

   OriginalPaper 15 November 2012 Pages: 617 - 620

2. Reassessing Quality-of-Life Instruments in the Evaluation of New Drugs

   • Gordon H. Guyatt
   • Roman J. Jaeschke

   Current Opinion 15 November 2012 Pages: 621 - 626

3. The Danish Approach to Standards For Economic Evaluation Methodologies

   • Anita Alban
   • Marlene Gyldmark
   • Jes Søgaard

   Leading Article 15 November 2012 Pages: 627 - 636

4. Assessing Antibacterial Pharmacoeconomics in the Intensive Care Unit

   • Mary C. Birmingham
   • James M. Hassett
   • Joseph A. Paladino

   Review Article 15 November 2012 Pages: 637 - 647

5. Do Practice Guidelines Augment Drug Utilisation Review?

   • Elizabeth A. Chrischilles
   • Kathleen Gondek

   Review Article 15 November 2012 Pages: 648 - 666

6. Application of the Findings of the European Stroke Prevention Study 2 (ESPS-2) to a New Zealand Ischaemic Stroke Cost Analysis

   • Guy Scott
   • Helen M. Scott

   Original Research Article 15 November 2012 Pages: 667 - 674

7. Measuring Patient Benefit From Botulinum Toxin in the Treatment of Dystonia

   • Claire M. Gudex
   • Maurice R. Hawthorne
   • Philip O. F. Duffey

   Original Research Article 15 November 2012 Pages: 675 - 684

8. Quality Assessment of Economic Evaluations Published in Pharmacoeconomics

   • Michael Iskedjian
   • Kostas Trakas
   • Thomas R. Einarson

   Original Research Article 15 November 2012 Pages: 685 - 694

9. Costs of Treating Dystonias and Hemifacial Spasm with Botulinum Toxin A

   • Richard C. Dodel
   • Annette Kirchner
   • Wolfgang H. Oertel

   Original Research Article 15 November 2012 Pages: 695 - 706